Patent · US Active

Treatment of migraine

US12220408B2 · kind B2 · utility

2Cited by

37References

30Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Mary Ann Johnson · Norristown, US
Leonardo R. Allain · Lansdale, US
W. Mark Eickhoff · Downingtown, US
Craig B. Ikeda · Harleysville, US
Chad D. Brown · Quakertown, US
Francis J. Flanagan, JR. · North Wales, US
Rebecca Nofsinger · Lansdale, US
Melanie Marota · Mount Laurel, US
Lisa Lupton · South San Francisco, US
Paresh B. Patel · Langhorne, US
Hanmi Xi · Furlong, US
Wei Xu · Saginaw, US

Key dates

Filing date	Jul 18, 2024
Grant date	Feb 11, 2025
Priority date	—
Expiry date	Jul 18, 2044

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/06
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure provides methods for the acute treatment of migraine with or without aura, comprising the administration of ubrogepant. In particular, the present disclosure provides methods for the acute treatment of migraine in patients having hepatic impairment; in patients with renal impairment; and in patients concurrently taking CYP3A4 modulators or BCRP and/or P-gp only inhibitors.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.